LINX Wales today announced it now has a fully functioning point of presence (PoP) at the NGD hyperscale data centre near Newport. This follows the previous announcement at the London Internet Exchange (LINX) member conference in London that Next Generation Data (NGD) – now part of Vantage Data Centers – was to become the home… Read More: Next Generation Data Centre, Newport named ‘Home of LINX Wales’… »
Amid daily headlines about COVID-19 vaccines and trends, Gilead’s Veklury, also known as remdesivir, remains the only antiviral drug authorized to treat the illness. With a new move from the FDA, the medicine’s emergency green light is a little broader—despite some lingering questions about its efficacy. Under the expanded emergency use authorization (EUA), all hospitalized… Read More: Gilead’s Veklury wins expanded FDA nod for moderate COVID-19 patients… »
Late to the party against its SGLT2 diabetes rivals, Merck & Co.’s Steglatro has also tracked way behind in the class’ growing presence in heart failure. Now, the drugmaker has posted new data showing Steglatro could, in fact, show benefits in that indication—but it’s a limited window into the future. Steglatro cut heart failure patients’ risk… Read More: ESC: Merck’s Steglatro shows limited promise with heart failure hospitalization… »
With hospital budgets decimated from COVID-related surgery cancellations, CIOs are looking for every possible way to cut costs. One obvious step is to stop paying for applications that are no longer part of an organization’s go-forward strategy. In this timely webinar, our panel of experts will help you: Understand the costs of running a legacy… Read More: Finding Cost Savings with Legacy Data Management »